Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-107010
Filing Date
2025-08-12
Accepted
2025-08-12 10:48:21
Documents
89
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q tsha-20250630.htm   iXBRL 10-Q 2535410
2 EX-31.1 tsha-ex31_1.htm EX-31.1 17774
3 EX-31.2 tsha-ex31_2.htm EX-31.2 17810
4 EX-32.1 tsha-ex32_1.htm EX-32.1 10304
5 EX-32.2 tsha-ex32_2.htm EX-32.2 10340
6 GRAPHIC img40495577_0.jpg GRAPHIC 139168
7 GRAPHIC img40495577_1.jpg GRAPHIC 283036
8 GRAPHIC img40495577_2.jpg GRAPHIC 38831
9 GRAPHIC img40495577_3.jpg GRAPHIC 261187
10 GRAPHIC img40495577_4.jpg GRAPHIC 26398
11 GRAPHIC img40495577_5.jpg GRAPHIC 129089
12 GRAPHIC img40495577_6.jpg GRAPHIC 201861
13 GRAPHIC img40495577_7.jpg GRAPHIC 48174
  Complete submission text file 0000950170-25-107010.txt   14033270

Data Files

Seq Description Document Type Size
14 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tsha-20250630.xsd EX-101.SCH 1691609
92 EXTRACTED XBRL INSTANCE DOCUMENT tsha-20250630_htm.xml XML 2107110
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39536 | Film No.: 251205003
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)